Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and Tesaro

NEW YORK, October 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Omeros Corporation (NASDAQ: OMER), and Tesaro, Inc. (NASDAQ: TSRO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On October 10, 2013, BioMarin Pharmaceuticals Inc. (BioMarin) announced that its CEO, Jean-Jacques Bienaimé, will host a conference call on October 24, at 5:00 p.m. ET to discuss Q3 2013 financial results. BioMarin reported that the live audio webcast and its replay (archived on the site for one week following the call) will be available on its website, under the investor section. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN]

--

Alnylam Pharmaceuticals, Inc. Research Report

On October 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP). The Company stated that it expects to file an Investigational New Drug application for this RNAi therapeutic in 2014. Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam, commented, "We are very pleased to advance ALN-AS1 as a new Development Candidate in our 'Alnylam 5x15' pipeline, with the goal of filing an IND in 2014. Our new pre-clinical data show that subcutaneous administration of ALN-AS1 results in complete suppression of the toxic heme biosynthesis intermediates that cause the symptoms and pathology of AIP." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5b29_ALNY]

--

Aegerion Pharmaceuticals, Inc. Research Report

On October 10, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it will host a conference call and live audio webcast on October 30, 2013 at 8:30 a.m. EDT to discuss its Q3 2013 financial and operational results and to provide a business update. The Company stated that the call can be accessed through its website under the "Investors" section. The call will also be archived on Aegerion's website for 30 days after the call. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a3f6_AEGR]

--

Omeros Corporation Research Report

On October 8, 2013, Omeros Corporation (Omeros) announced the appointment of Michael K. Inouye as Vice President of Commercial Operations. The Company stated that Mr. Inouye has over 20 years of management experience in the pharmaceutical industry, and has previously served as Senior Vice President, Corporate and Commercial Development for Pharmacyclics, and Senior Vice President, Commercial Operations at Telik. Commenting on the appointment, Gregory A. Demopulos, M.D., Omeros' Chairman and CEO said, "With his deep expertise in building commercial organizations and his proven track record of successful drug-product launches, Mike is an important part of our team as we prepare for and execute the 2014 planned launch of OMS302. Given his breadth of experience, I expect that Mike will also play a key role in advancing the rest of our pipeline toward commercialization." The Full Research Report on Omeros Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e3c9_OMER]

--

Tesaro, Inc. Research Report

On September 30, 2013, Tesaro, Inc. (Tesaro) announced that an open label, dose-finding and escalation study has been initiated to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV) formulation of rolapitant in healthy volunteers. According to Tesaro, Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Company stated that the data from the Phase 1 study will be used to select the intravenous dose that will be advanced into a subsequent clinical study. Mary Lynne Hedley, Ph.D., President of Tesaro, said, "We are pleased to be advancing both oral and IV formulations of rolapitant. Intravenous antiemetic formulations comprise approximately 80% of the CINV market opportunity and enable healthcare providers to ensure that their patients receive medication to prevent chemotherapy-induced nausea and vomiting when administered immediately prior to treatment." The Full Research Report on Tesaro, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4258_TSRO]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner